Free tool
Oncology stocks
We cover 262 companies grouped under the Oncology theme. The median market value in the group is $82.45M. Across the group, the median move over the past trading day is +1.01%. 43% of the 253 with a 200-day average trade above it. Price change over the past year runs from −77.9% to +153.3% across the middle 80 percent of the group, with a median of −11.3%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
262 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 129.28 EUR | +11.62% | +44.70% | +83.96% |
| MRK | Merck & Co., Inc. | $156.45 | +19.65% | +48.06% | +88.17% |
| AZN.L | AstraZeneca PLC | 12,110.00 GBP | −6.41% | −10.89% | +1.98% |
| AZN | AstraZeneca PLC | $169.66 | +0.01% | −6.39% | +7.60% |
| A1ZN34.SA | AstraZeneca PLC | 144.34 BRL | +0.85% | −12.75% | +1.51% |
| ZYME | Zymeworks Inc. | $27.47 | +19.43% | +3.19% | +88.54% |
| IMCR | Immunocore Holdings plc | $37.40 | +10.75% | +10.72% | +14.76% |
| DMRA | Damora Therapeutics, Inc. | $30.62 | +4.01% | +40.33% | +800.59% |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.41% | −12.36% | −44.50% |
| VIR | Vir Biotechnology, Inc. | $10.71 | +21.70% | +80.30% | +144.52% |
| INBX | Inhibrx Biosciences, Inc. | $122.72 | +48.84% | +63.54% | +390.10% |
| SNDX | Syndax Pharmaceuticals, Inc. | $19.92 | −2.92% | −6.48% | +27.20% |
| BCAX | Bicara Therapeutics Inc. | $24.58 | −11.61% | +50.06% | +117.14% |
| AAPG | Ascentage Pharma Group Internat | $16.79 | −11.12% | −36.33% | −61.38% |
| AVBP | ArriVent BioPharma, Inc. | $31.35 | +3.95% | +50.72% | +62.02% |
| REPL | Replimune Group, Inc. | $15.80 | +83.08% | +77.53% | +187.80% |
| AKTS | Aktis Oncology, Inc. | $26.69 | +10.24% | +19.15% | +19.15% |
| CGEM | Cullinan Therapeutics, Inc. | $22.95 | +31.67% | +126.78% | +200.39% |
| ORIC | ORIC Pharmaceuticals, Inc. | $13.83 | +15.06% | +69.28% | +43.76% |
| DRTS | Alpha Tau Medical Ltd. | $14.70 | +20.39% | +204.35% | +357.94% |
| IMTX | Immatics N.V. | $9.24 | +7.07% | −11.58% | +76.67% |
| GLUE | Monte Rosa Therapeutics, Inc. | $14.56 | −35.46% | −4.90% | +217.21% |
| CRVS | Corvus Pharmaceuticals, Inc. | $14.56 | +12.69% | +98.91% | +167.16% |
| 0HFQ.L | AnaptysBio, Inc. | $56.87 | −3.20% | +24.44% | +183.92% |
| 2160.T | GNI Group Ltd. | 2,765.00 JPY | +12.58% | +20.74% | +4.54% |
| JANX | Janux Therapeutics, Inc. | $18.68 | +19.97% | +36.85% | −18.82% |
| PHIL.MI | Philogen S.p.A. | 23.35 EUR | −2.71% | +3.88% | +2.12% |
| KURA | Kura Oncology, Inc. | $13.59 | +33.89% | +31.49% | +77.65% |
| CADL | Candel Therapeutics, Inc. | $13.60 | +36.55% | +150.00% | +138.18% |
| GERN | Geron Corporation | $1.55 | +4.73% | +17.42% | +9.15% |
| EUZ.DE | Eckert & Ziegler SE | 13.65 EUR | −0.29% | −9.06% | −23.06% |
| OLMA | Olema Pharmaceuticals, Inc. | $10.91 | −9.16% | −56.84% | +95.17% |
| 4587.T | PeptiDream Inc. | 1,135.00 JPY | +22.00% | −29.98% | −28.26% |
| ANL | Adlai Nortye Ltd. | $13.74 | +13.93% | +895.65% | +737.80% |
| RIGL | Rigel Pharmaceuticals, Inc. | $46.75 | +25.03% | +11.76% | +14.75% |
| AURA | Aura Biosciences, Inc. | $7.82 | +9.22% | +47.55% | +19.94% |
| NVCT | Nuvectis Pharma, Inc. | $25.89 | +32.50% | +204.23% | +298.92% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.37 | +7.09% | −23.76% | −3.50% |
| MNPR | Monopar Therapeutics Inc. | $110.82 | +0.44% | +67.88% | +264.30% |
| CTMX | CytomX Therapeutics, Inc. | $3.37 | +3.69% | −20.71% | +68.50% |
| 4588.T | Oncolys BioPharma Inc. | 4,130.00 JPY | +65.80% | +176.44% | +526.71% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $11.16 | +4.01% | +42.04% | +5.13% |
| GUD.TO | Knight Therapeutics Inc. | 9.75 CAD | −0.71% | +64.97% | +49.08% |
| EIKN | Eikon Therapeutics, Inc. | $12.55 | +27.02% | −16.33% | −16.33% |
| 0QAV.L | Nanobiotix S.A. | 34.51 EUR | −2.83% | +80.19% | +346.30% |
| CU6.AX | Clarity Pharmaceuticals Ltd | 2.48 AUD | +16.98% | −33.15% | −27.91% |
| VSTM | Verastem, Inc. | $7.08 | +16.45% | −2.07% | −21.16% |
| SGMT | Sagimet Biosciences Inc. | $10.29 | +38.12% | +71.79% | +45.34% |
| CBIO | Crescent Biopharma, Inc. | $17.00 | +0.41% | +53.43% | +15.65% |
| ARVN | Arvinas, Inc. | $9.60 | +16.79% | −16.30% | +28.34% |
| DCTH | Delcath Systems, Inc. | $16.92 | +41.71% | +70.05% | +55.37% |
| 0KCS.L | OPKO Health, Inc. | $1.51 | +2.03% | +16.20% | +5.63% |
| PRLD | Prelude Therapeutics Incorporated | $6.59 | +69.41% | +141.39% | +418.90% |
| CCCC | C4 Therapeutics, Inc. | $4.20 | +16.99% | +117.62% | +66.01% |
| TOI | Starling Oncology Inc | $6.20 | +19.46% | +68.94% | +78.67% |
| 0IL8.L | Kyntra Bio, Inc. | $7.95 | +1.50% | −11.24% | −24.41% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.02 EUR | −0.97% | −91.09% | −91.09% |
| RLMD | Relmada Therapeutics, Inc. | $4.59 | −11.73% | +5.03% | +635.58% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.79 EUR | +5.76% | +374.47% | +1150.00% |
| PBYI | Puma Biotechnology, Inc. | $9.32 | +16.65% | +61.53% | +86.77% |
| 0LOV.L | Verastem, Inc. | $7.14 | +3.48% | −1.92% | −21.47% |
| CMPX | Compass Therapeutics, Inc. | $2.53 | +21.63% | −51.06% | −16.23% |
| AVCT.L | Avacta Group Plc | 68.80 GBP | +0.44% | +19.65% | +32.31% |
| FENC | Fennec Pharmaceuticals Inc. | $11.71 | +14.69% | +52.47% | +35.38% |
| FHTX | Foghorn Therapeutics Inc. | $6.85 | +31.73% | +31.98% | +30.48% |
| PRTC.L | PureTech Health plc | 118.80 GBP | +0.51% | −4.65% | −11.34% |
| GALT | Galectin Therapeutics Inc. | $3.99 | +18.05% | −1.48% | −0.25% |
| FRX.TO | Fennec Pharmaceuticals Inc. | 15.49 CAD | +5.73% | +48.80% | +27.38% |
| AGEN | Agenus Inc. | $8.36 | +36.38% | +158.82% | +90.43% |
| CATX | Perspective Therapeutics, Inc. | $3.29 | +16.67% | +17.92% | −4.91% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $3.88 | −13.97% | +183.21% | +113.19% |
| STRO | Sutro Biopharma, Inc. | $21.44 | −10.70% | +95.62% | +155.24% |
| 0XOD.L | UroGen Pharma Ltd. | $46.35 | −1.31% | +105.18% | +136.32% |
| IMRX | Immuneering Corporation | $5.23 | +19.95% | −21.00% | −12.10% |
| BCYC | Bicycle Therapeutics plc | $4.39 | +11.14% | −34.28% | −38.34% |
| RAC.AX | Racura Oncology Ltd | 2.15 AUD | +5.39% | −25.09% | +72.00% |
| WHWK | Whitehawk Therapeutics, Inc. | $5.08 | +37.30% | +108.20% | +198.82% |
| ALXO | ALX Oncology Holdings Inc. | $2.00 | −0.99% | +73.91% | +81.82% |
| CGEN | Compugen Ltd. | $2.87 | +20.59% | +85.16% | +100.70% |
| MGNX | MacroGenics, Inc. Common Stock | $4.17 | +4.25% | +159.01% | +154.27% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.40% | −15.23% | −16.98% |
| GLSI | Greenwich LifeSciences, Inc. | $18.59 | +38.32% | −4.52% | +56.35% |
| 0IV3.L | Geron Corporation | $1.54 | 0.00% | +16.67% | +8.41% |
| PYXS | Pyxis Oncology, Inc. | $3.06 | +5.15% | +166.09% | +120.14% |
| IPHA | Innate Pharma S.A. | $2.27 | +28.10% | +24.73% | +1.34% |
| SPL.AX | Starpharma Holdings Limited | 0.74 AUD | −1.34% | +101.37% | +465.38% |
| ADAG | Adagene Inc. | $3.82 | +8.22% | +107.61% | +62.55% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +17.37% | +16.21% | +1.84% |
| TARA | Protara Therapeutics, Inc. | $3.97 | −1.73% | −26.21% | +30.16% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $11.31 | +24.56% | +43.71% | +14.36% |
| NBP | NovaBridge Biosciences | $1.93 | +8.43% | −54.80% | −59.96% |
| CHRS | Coherus Oncology, Inc. | $1.37 | −6.16% | 0.00% | +17.09% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +4.07% | −17.21% | −24.30% |
| MENS | Jyong Biotech Ltd. | $2.23 | −8.23% | −34.60% | −95.26% |
| CUE | Cue Biopharma, Inc. | $26.76 | −17.84% | +164.69% | +9.05% |
| MOLN | Molecular Partners AG | $4.38 | +9.36% | +3.79% | +3.91% |
| KZIA | Kazia Therapeutics Limited | $13.79 | +12.94% | +175.80% | +83.87% |
| OKUR | OnKure Therapeutics, Inc. | $3.85 | −4.94% | +30.07% | +36.77% |
| ASRT | Assertio Holdings Inc | $23.50 | 0.00% | +157.11% | +98.31% |
| INDP | Indaptus Therapeutics, Inc. | $1.10 | −46.32% | −60.04% | −84.51% |
| 0IMT.L | Photocure ASA | 53.80 NOK | +0.35% | −25.59% | −12.59% |
| HPHA.DE | Heidelberg Pharma AG | 2.53 EUR | −1.17% | +1.20% | −44.40% |
| SCLP.L | Scancell Holdings plc | 9.80 GBP | −1.51% | −1.01% | −6.67% |
| ADCT | ADC Therapeutics SA | $1.04 | −8.77% | −70.45% | −66.34% |
| HURA | TuHURA Biosciences, Inc. | $2.04 | −7.69% | +172.00% | −30.85% |
| 0RU5.L | Oncoinvent ASA | 70.20 NOK | −18.37% | +61.75% | +5951.72% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 72.40 PLN | −2.95% | −3.47% | +76.16% |
| LIXT | Nomad Power Solutions Inc | $4.15 | −6.74% | +8.07% | +26.14% |
| BDTX | Black Diamond Therapeutics, Inc. | $2.24 | +29.48% | −10.04% | −21.95% |
| ANIX | Anixa Biosciences, Inc. | $3.66 | +5.78% | +15.82% | +22.00% |
| GNLX | Genelux Corporation | $2.72 | −7.80% | −40.22% | −27.27% |
| NTHI | NeOnc Technologies Holdings, Inc. | $4.71 | +36.92% | −46.96% | −18.72% |
| 0RDB.L | Oryzon Genomics S.A. | 2.84 EUR | +0.92% | −11.03% | +4.08% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.80 PLN | +25.33% | −30.76% | −34.72% |
| 4889.T | Renascience Inc. | 1,378.00 JPY | −7.70% | −3.57% | −37.68% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −80.71% |
| HBP.TO | Helix BioPharma Corp. | 1.99 CAD | +38.19% | −17.08% | +35.37% |
| ONCY | Oncolytics Biotech Inc. | $0.86 | +7.68% | −12.10% | −12.99% |
| AMAN | Amanat Acquisition Corp | $10.69 | +5.32% | +6.79% | +6.79% |
| JATT | JATT II Acquisition Corp. | $12.46 | +11.80% | +18.62% | +18.62% |
| 4575.T | CanBas Co., Ltd. | 821.00 JPY | +12.47% | +0.24% | −40.51% |
| ACRV | Acrivon Therapeutics, Inc. | $2.18 | +39.74% | −11.38% | +63.91% |
| 4579.T | RaQualia Pharma Inc. | 571.00 JPY | +26.05% | −41.26% | +4.58% |
| OSE.PA | OSE Immunotherapeutics SA | 3.19 EUR | +0.69% | −39.85% | −47.82% |
| MAIA | MAIA Biotechnology, Inc. | $1.41 | +10.16% | −11.88% | −10.76% |
| CTOR | Citius Oncology, Inc. | $0.81 | +45.70% | −24.99% | −57.14% |
| 0QW5.L | Heidelberg Pharma AG | 2.46 EUR | +3.36% | −2.38% | −45.58% |
| VRCA | Verrica Pharmaceuticals Inc. | $4.94 | −7.66% | −40.48% | −17.53% |
| 0J4V.L | Heron Therapeutics, Inc. | $0.32 | +1.38% | −74.92% | −76.73% |
| POLB.L | Poolbeg Pharma PLC | 8.50 GBP | +38.21% | +117.95% | +161.54% |
| 4888.T | Stella Pharma Corporation | 364.00 JPY | +17.42% | +71.70% | −9.23% |
| CRDF | Cardiff Oncology, Inc. | $1.02 | +21.43% | −61.65% | −53.85% |
| 0QXX.L | Molecular Partners AG | 3.51 CHF | +2.33% | +3.54% | +22.73% |
| ELTX | Elicio Therapeutics, Inc. | $3.01 | +0.33% | −62.61% | −72.71% |
| APLM | Apollomics, Inc. | $26.50 | +47.22% | +37.31% | +318.64% |
| OSTX | OS Therapies Incorporated | $1.65 | +7.84% | +23.13% | −24.66% |
| PLRX | Pliant Therapeutics, Inc. | $1.14 | +5.56% | −8.80% | −23.49% |
| SAR.L | Sareum Holdings plc | 29.00 GBP | +31.82% | +70.59% | +38.10% |
| XBIT | XBiotech Inc. | $2.30 | +1.77% | −3.36% | −28.13% |
| PMVP | PMV Pharmaceuticals, Inc. | $1.31 | +10.59% | +6.10% | −8.10% |
| BOLD | Boundless Bio, Inc. | $2.94 | +18.55% | +140.98% | +160.18% |
| MAAT.PA | MaaT Pharma SA | 3.05 EUR | +8.75% | −45.43% | −39.58% |
| RNXT | RenovoRx, Inc. | $1.42 | +47.15% | +70.06% | +58.13% |
| HRTX | Heron Therapeutics, Inc. | $0.32 | −29.76% | −74.36% | −76.59% |
| XLO | Xilio Therapeutics, Inc. | $9.08 | −0.11% | −3.49% | −7.35% |
| IMM.AX | Immutep Limited | 0.05 AUD | +14.89% | −87.44% | −77.96% |
| ATX.AX | Amplia Therapeutics Limited | 0.15 AUD | +13.08% | −13.53% | −13.53% |
| IMMP | Immutep Limited | $0.38 | +0.50% | −87.05% | −77.54% |
| 4572.T | Carna Biosciences, Inc. | 416.00 JPY | +40.54% | +3.48% | +83.26% |
| 0OCQ.L | Transgene SA | 0.81 EUR | −0.25% | −16.36% | −18.38% |
| COIL.L | Coiled Therapeutics plc | 9.50 GBP | −5.00% | −20.83% | −26.92% |
| 4564.T | OncoTherapy Science, Inc. | 21.00 JPY | +5.00% | 0.00% | −25.00% |
| 0RAD.L | OSE Immunotherapeutics SA | 3.16 EUR | −2.11% | −40.40% | −48.92% |
| TIL | Instil Bio, Inc. | $7.81 | +9.23% | −30.70% | −69.62% |
| 4597.T | Solasia Pharma K.K. | 29.00 JPY | 0.00% | +3.57% | −23.68% |
| PTX.AX | Prescient Therapeutics Limited | 0.07 AUD | −15.00% | −18.07% | +58.14% |
| CANTA.ST | Cantargia AB (publ) | 1.90 SEK | +1.71% | −53.86% | −28.93% |
| IBO | Impact BioMedical Inc. | $0.46 | +6.53% | −11.33% | −20.79% |
| BKHA | Black Hawk Acquisition Corporation | $11.89 | −1.74% | +5.69% | +8.09% |
| SVE.WA | Synthaverse S.A. | 3.04 PLN | +10.55% | −20.73% | −37.70% |
| 4594.T | BrightPath Biotherapeutics Co., Ltd. | 53.00 JPY | +12.77% | +8.16% | −33.75% |
| HOWL | Werewolf Therapeutics, Inc. | $0.89 | +96.47% | +37.98% | −35.04% |
| 4583.T | Chiome Bioscience Inc. | 85.00 JPY | +25.00% | −20.56% | −36.57% |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $1.92 | −72.92% | −73.30% | −69.57% |
| MOC.WA | Molecure S.A. | 6.14 PLN | +2.33% | −6.40% | −21.18% |
| CNTX | Context Therapeutics Inc. | $0.44 | −30.00% | −71.91% | −50.13% |
| 206A.T | PRISM BioLab Co.,LTD | 171.00 JPY | +16.33% | +6.21% | −6.56% |
| SNT.AX | Syntara Limited | 0.03 AUD | +18.18% | −23.53% | −1.89% |
| 190A.T | CHORDIA THERAPEUTICS INC | 75.00 JPY | 0.00% | −33.04% | −58.56% |
| ATNM | Actinium Pharmaceuticals, Inc. | $1.08 | +26.46% | −21.17% | −39.66% |
| BCTX | BriaCell Therapeutics Corp. | $3.77 | +6.20% | −47.42% | −49.67% |
| KYNB | Kyntra Bio, Inc. | $8.10 | +14.89% | −11.57% | −23.80% |
| BCT.TO | BriaCell Therapeutics Corp. | 5.14 CAD | +1.98% | −47.66% | −50.62% |
| 4582.T | SymBio Pharmaceuticals Limited | 63.00 JPY | −7.35% | −30.00% | −58.28% |
| BYSI | BeyondSpring Inc. | $0.72 | −38.44% | −55.27% | −60.43% |
| MDNA.TO | Medicenna Therapeutics Corp. | 0.47 CAD | +36.23% | −53.00% | −58.77% |
| EVAX | Evaxion A/S | $3.35 | +15.92% | −28.87% | +4.49% |
| LTRN | Lantern Pharma Inc. | $2.18 | −21.86% | −29.90% | −52.30% |
| NNG.WA | NanoGroup S.A. | 2.47 PLN | +2.28% | −7.84% | −14.09% |
| NXTC | NextCure, Inc. | $5.91 | +15.43% | −55.50% | +13.33% |
| PSTV | Plus Therapeutics Inc | $3.84 | +2.90% | −72.59% | −68.67% |
| ATOS | Atossa Therapeutics, Inc. | $2.68 | +13.56% | −71.64% | −76.49% |
| CVM | CEL-SCI Corporation | $1.48 | +25.42% | −71.26% | −85.98% |
| IMU.AX | Imugene Limited | 0.07 AUD | −16.28% | −81.54% | −73.33% |
| MRKR | Marker Therapeutics, Inc. | $1.52 | +24.59% | −1.30% | +20.63% |
| CLRB | Cellectar Biosciences, Inc. | $2.54 | +4.96% | −26.80% | −45.96% |
| BFRI | Biofrontera Inc. | $1.51 | +43.81% | +108.28% | +63.77% |
| CCM | Concord Medical Services Holdings Limited | $4.95 | +9.76% | +15.93% | −10.65% |
| ABVC | ABVC BioPharma, Inc. | $0.80 | −21.58% | −63.47% | −72.70% |
| ALLR | Allarity Therapeutics, Inc. | $1.33 | +8.13% | +16.67% | +41.34% |
| NOX.AX | Noxopharm Limited | 0.09 AUD | −8.00% | −2.13% | −20.00% |
| DEX.ST | DexTech Medical AB | 10.40 SEK | −0.95% | +12.43% | +20.93% |
| RADX | Radiopharm Theranostics Limited | $2.48 | −32.24% | −51.94% | −55.71% |
| TPST | Tempest Therapeutics, Inc. | $1.11 | +18.72% | −62.37% | −89.50% |
| B8FK.DE | Biofrontera AG | 2.52 EUR | −1.95% | −1.18% | −4.55% |
| ABERA.ST | Abera Bioscience AB | 8.14 SEK | −7.29% | +13.06% | −0.12% |
| 4882.T | Perseus Proteomics Inc. | 149.00 JPY | +2.76% | −34.65% | −56.43% |
| RAD.AX | Radiopharm Theranostics Limited | 0.01 AUD | −33.33% | −60.00% | −62.96% |
| CTXR | Citius Pharmaceuticals, Inc. | $0.60 | +16.77% | −28.81% | −52.09% |
| MDCX | Medicus Pharma Ltd. | $0.26 | −17.92% | −83.69% | −87.97% |
| INTS | Intensity Therapeutics, Inc. | $4.90 | +7.11% | −51.89% | −37.24% |
| LSTA | Lisata Therapeutics, Inc. | $1.74 | +20.83% | −11.22% | −31.23% |
| ACTI.ST | Active Biotech AB (publ) | 5.55 SEK | +7.77% | +20.65% | −60.62% |
| AKTX | Akari Therapeutics, Plc | $7.87 | −6.97% | −32.16% | −77.77% |
| ALTME.PA | TME Pharma N.V. | 0.16 EUR | +147.62% | +126.09% | +48.57% |
| PHIO | Phio Pharmaceuticals Corp. | $1.17 | +11.43% | +7.34% | −41.21% |
| GTBP | GT Biopharma, Inc. | $0.30 | −10.27% | −63.32% | −72.50% |
| BLRX | BioLineRx Ltd. | $2.85 | +1.06% | +1.79% | −25.97% |
| CRTX.L | CRISM Therapeutics Corporation | 11.50 GBP | +21.05% | +15.00% | +9.52% |
| PDSB | PDS Biotechnology Corporation | $0.22 | −68.04% | −73.41% | −82.96% |
| MBRX | Moleculin Biotech, Inc. | $0.61 | −72.10% | −83.12% | −95.75% |
| TOVX | Theriva Biologics, Inc. | $0.24 | +11.95% | −9.58% | −45.33% |
| APRE | Aprea Therapeutics, Inc. | $0.95 | +51.98% | +11.36% | −40.63% |
| 0NWK.L | Valerio Therapeutics Société anonyme | 0.82 EUR | +3.03% | +393.94% | +1214.52% |
| LNAI | Lunai Bioworks Inc. | $2.20 | −1.35% | −71.71% | −87.99% |
| PUR.WA | MultiQure S.A. | 3.14 PLN | +45.81% | −23.35% | −53.66% |
| 4598.T | Delta-Fly Pharma, Inc. | 104.00 JPY | +5.05% | −80.92% | −81.94% |
| XBIO | Xenetic Biosciences, Inc. | $3.82 | +52.80% | +77.67% | +33.57% |
| IMNN | Imunon, Inc. | $1.66 | +8.50% | −57.97% | −73.86% |
| CNSP | CNS Pharmaceuticals, Inc. | $5.80 | +14.40% | +9.43% | −11.31% |
| AIM | AIM ImmunoTech Inc. | $0.25 | +1.60% | −77.99% | −89.97% |
| PAB.AX | Patrys Limited | 0.03 AUD | −22.50% | +14.81% | −11.43% |
| CURX | Curanex Pharmaceuticals Inc | $4.75 | +2495.63% | +1190.76% | +18.16% |
| BOLT | Bolt Biotherapeutics, Inc. | $3.85 | −3.12% | −33.51% | −29.28% |
| CANF | Can-Fite BioPharma Ltd. | $3.32 | +5.40% | −24.55% | −74.46% |
| ALOPM.PA | Oncodesign Precision Medicine Société anonyme | 0.32 EUR | +1.26% | −17.65% | −17.01% |
| CHOSA.ST | CHOSA Oncology AB | 0.73 SEK | −14.59% | −20.22% | −12.00% |
| ITOC | iTonic Holdings Ltd. | $0.27 | +9.68% | −37.07% | −51.75% |
| LIMN | Liminatus Pharma, Inc. | $4.61 | +4375.73% | +619.19% | +35.59% |
| NCNA | NuCana plc | $1.47 | +16.67% | −59.62% | −56.76% |
| PCSA | Processa Pharmaceuticals, Inc. | $2.18 | −15.83% | −25.60% | −60.36% |
| KAPA | Kairos Pharma, Ltd. | $0.25 | −19.94% | −65.95% | −79.82% |
| 0GP7.L | Medivir AB (publ) | 2.08 SEK | +9.14% | +355.54% | +3.85% |
| NFX.L | Nuformix plc | 0.17 GBP | +3.13% | −44.07% | +106.25% |
| PER.AX | PERCHERON FPO [PER] | 0.01 AUD | +25.00% | −47.37% | −54.55% |
| BCAB | BioAtla, Inc. | $3.26 | −4.12% | −87.79% | −81.69% |
| HCWB | HCW Biologics Inc. | $2.60 | −1.89% | +132.14% | −53.15% |
| APVO | Aptevo Therapeutics Inc. | $2.46 | −41.57% | −73.80% | −92.81% |
| APS.TO | Aptose Biosciences Inc | 2.40 CAD | 0.00% | +18.81% | +37.14% |
| OSRH | OSR Health, Inc. | $0.12 | −73.09% | −80.22% | −88.47% |
| CRIS | Curis, Inc. | $1.59 | −66.10% | +62.24% | −3.64% |
| DBP-B.ST | Double Bond Pharmaceutical Int. | 0.15 SEK | +18.62% | +9.33% | +9.33% |
| RDHL | RedHill Biopharma Ltd. | $0.61 | −13.56% | −41.25% | −55.83% |
| CLDI | Calidi Biotherapeutics, Inc. | $1.31 | −25.57% | +11.02% | −16.03% |
| GOVX | GeoVax Labs, Inc. | $0.64 | −15.54% | −87.60% | −96.61% |
| ARTL | Artelo Biosciences, Inc. | $0.72 | −28.99% | −81.18% | −97.47% |
| IVX.AX | Invion Limited | 0.04 AUD | −15.22% | −58.06% | −70.00% |
| VAL.L | ValiRx plc | 0.16 GBP | −3.13% | −57.53% | −73.04% |
| NXTS | Nexentis Technologies Inc. | $1.85 | +10.78% | −83.38% | −96.64% |
| PPBT | Purple Biotech Ltd | $1.65 | +14.58% | −75.00% | −92.53% |
| RNAZ | TransCode Therapeutics, Inc. | $2.53 | −53.58% | −65.81% | −74.16% |
| PPCB | Propanc Biopharma, Inc. | $1.13 | −14.39% | −92.09% | −98.66% |
| 0RK9.L | Alligator Bioscience AB (publ) | 0.03 SEK | −1.31% | −91.40% | −99.22% |
| SLXN | Silexion Therapeutics Corp | $0.37 | −85.57% | −80.59% | −94.88% |
| NX1.AX | Nexalis Therapeutics Limited | 0.01 AUD | 0.00% | −50.00% | −50.00% |
| DCOY | Decoy Therapeutics Inc. | $2.98 | −20.32% | −61.91% | −95.58% |
| ATORX.ST | Alligator Bioscience AB (publ) | 0.03 SEK | −28.13% | −91.12% | −99.30% |
| PTP.DE | Pentixapharm Holding AG N | 1.88 EUR | −4.57% | +22.08% | +8.55% |
| BDRX | Biodexa Pharmaceuticals Plc | $1.18 | −24.84% | −90.41% | −96.20% |
| 0GQU.L | Active Biotech AB (publ) | 5.46 SEK | +5.61% | +7801.59% | +7801.59% |
| APM | Aptorum Group Ltd | $8.41 | −6.45% | +685.98% | +260.94% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.